Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20623370 | 0.94 | TLR7 (0.89) | TLR7TLR8 | |
| SCHEMBL3817941 | 0.93 | TLR7 (0.87) | TLR7TLR8 | |
| SCHEMBL1951699 | 0.92 | TLR7 (0.93) | TLR7TLR8 | |
| SCHEMBL5350451 | 0.92 | TLR7 (0.79) | TLR7TLR8 | |
| SCHEMBL5353790 | 0.92 | TLR7 (0.79) | TLR7TLR8 | |
| SCHEMBL5360303 | 0.91 | TLR7 (0.80) | TLR7TLR8 | |
| SCHEMBL728266 | 0.91 | TLR7 (0.80) | TLR7TLR8 | |
| SCHEMBL1615627 | 0.91 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL2897067 | 0.91 | TLR7 (0.80) | TLR7TLR8 | |
| SCHEMBL6053125 | 0.90 | TLR7 (0.79) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507237-A1 | IMIDAZOQUINOLINES WHICH ACT VIA TOLL - LIKE RECEPTORS (TLR) | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-8093390-B2 | Substituted fused [1,2]imidazo[4,5-C] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090005371-A1 | Substituted Fused [1,2]Imidazo[4,5-C] Ring Compounds and Methods | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005371-A1 | Substituted Fused [1,2]Imidazo[4,5-C] Ring Compounds and Methods | IL2, IFNG, IL4 | TLR7 43/4885TLR8 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.